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Background: Diagnosis of early-stage hepatocellular carcinoma (HCC) followed by curative resection or liver
transplantation offers the best chance for long-term patient survival. Clinically, ultrasonography has suboptimal
sensitivity for detecting early-stage HCC. Several serological tests including alpha-fetoprotein (AFP), the ratio of lens
culinaris agglutinin-reactive alpha-fetoprotein to total AFP (AFP-L3/AFP), des-gamma carboxyprothrombin (DCP),
and glypican-3 (GPC-3) have been widely investigated as diagnostic biomarkers for early-stage HCC in at-risk
populations. However, these tests are not recommended for routine HCC screening. Our objective is to determine
the diagnostic performance of AFP, AFP-L3/AFP, DCP, and GPC-3 for the detection of HCC, particularly early-stage
tumors meeting the Milan criteria.
Methods/design: We will include cross-sectional studies that consecutively or randomly recruit target populations.
We will search the Cochrane Library, Medline, Embase, Science Citation Index, and the Chinese National Knowledge
Infrastructure. We will also search the MEDION and ARIF databases to identify diagnostic systematic reviews that
include primary studies. Reference lists of relevant reviews will be searched for additional trials. Language
restrictions will not be applied. Two reviewers will independently screen study eligibility and extract data.
Methodological quality will be assessed according to the revised tool for the Quality Assessment of Diagnostic
Accuracy Studies (QUADAS-2). Two authors will apply the QUADAS-2 assessment to all the included studies, and
any discrepancies will be resolved by the third author. The following test characteristics will be extracted into 2 × 2
tables for all included studies: true positives, false positives, true negatives, and false negatives. Study-specific
estimates of sensitivity and specificity with 95% confidence intervals will be displayed in forest plots. When possible,
we will use the bivariate random-effects model or the Rutter and Gatsonis hierarchical summary receiver operating
characteristic model for statistical analysis. To investigate heterogeneity, we will include study designs, population
characteristics, test characteristics, and types of reference standard as the study-level variables.
Discussion: Our systematic review will allow patients, clinicians, and researchers to determine the diagnostic
performance of AFP, AFP-L3/AFP, DCP, and GPC-3 for the detection of early-stage HCC and the potential roles of
these diagnostic biomarkers in the existing diagnostic pathways.
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Target condition being diagnosed
The incidence of primary liver cancer has increased globally
during the past two decades. Currently, liver cancer is the
third highest cause of cancer-related deaths worldwide and
accounts for 7% of all cancers [1]. Hepatocellular carcinoma
(HCC) represents more than 90% of liver cancers, and thus,
is a major contributor to global disease burden. Major
risk factors for developing HCC include infections with
hepatitis B virus (HBV) or hepatitis C virus, alcoholic liver
disease, and nonalcoholic fatty liver disease. Most of these
risk factors contribute to the development of liver cirrho-
sis, which is present in 80% to 90% of patients with HCC
[2]. Reports have shown that the 5-year cumulative risk
for the development of HCC in patients with liver cirrho-
sis ranges between 5% and 30% [3]. Despite advances in
surveillance and available treatments, there has been little
improvement in the survival rates of HCC patients; the
5-year survival rate of HCC patients remains below 12%
in the United States [2].
Diagnosis of early-stage HCC followed by curative
resection or liver transplantation offers the best chance
for long-term patient survival. Five-year survival rates of
70% have been achieved in HCC patients with preserved
hepatic function after surgical resection of single tumors
less than 5 cm in diameter [4]. In addition, 5-year survival
rates of more than 70% have been reported in patients with
HCC meeting the Milan criteria (single nodule <5 cm
or three nodules each <3 cm in diameter) after liver
transplantation [4,5]. Radiofrequency ablation has resulted
in 5-year survival rates of 37% in HCC patients who are
not eligible for surgical resection or liver transplantation
[4]. Nevertheless, survival rates of patients with advanced
HCC have dropped markedly to an average survival of less
than one per year [6]. Importantly, fewer than 30% of HCC
patients are diagnosed early enough during surveillance to
undergo surgical resection or liver transplantation [7].Index tests
Alpha-fetoprotein and lens culinaris agglutinin-reactive
alpha-fetoprotein
Alpha-fetoprotein (AFP) is the most widely investigated
biomarker for HCC diagnosis. Persistent elevation of
AFP has been shown to be a risk factor for developing
HCC and is used to help define at-risk populations [8].
However, AFP has suboptimal diagnostic performance
for HCC surveillance. In patients with liver cirrhosis,
fluctuating levels of AFP may reflect flare-ups of viralhepatitis, exacerbation of underlying liver disease, or
HCC development [9]. Additionally, only 10% to 20% of
early-stage HCC patients have abnormal AFP serum
levels. Recently, this small proportion of tumors has been
associated with a molecular subclass of aggressive HCC
(S2 class, EpCAM positive) [10-12]. AFP levels at a cutoff
value of 20 ng/ml demonstrate good sensitivity but low
specificity, whereas a cutoff value of 200 ng/ml provides
high specificity but a marked loss in sensitivity [13].
Lens culinaris agglutinin-reactive AFP (AFP-L3) is the
glycosylated subfraction of AFP and is more specific to
malignant hepatocytes than AFP [14]. Therefore, it may
be useful in distinguishing between elevations in AFP
due to benign conditions and HCC. AFP-L3, reported as
the ratio of AFP-L3 to total AFP (AFP-L3/AFP), of more
than 10% has been used as the cutoff value for HCC
diagnosis [15]. However, the sensitivity of AFP-L3/AFP
is low in cases where AFP is not markedly elevated [16].
Recently, highly sensitive AFP-L3 assay has been evaluated
in patients with an AFP level of <20 ng/ml [17]. The diag-
nostic sensitivity and specificity of highly sensitive AFP-L3
assay at a cutoff level of 5% were 41.5% and 85.1%, respect-
ively. In addition, many studies have investigated the role of
AFP-L3/AFP, alone or in combination with AFP and/or
des-gamma carboxyprothrombin (DCP), as a screening
marker for HCC [15,18-20]. The sensitivity of AFP-L3/AFP
has been shown to vary with tumor size [21].DCP
DCP, also known as prothrombin induced by vitamin K
absence II (PIVKA II), has been widely used as a sero-
logical marker for HCC detection over the last two
decades. In 1984, Liebmann and colleagues reported for
the first time the association of HCC with elevated
serum DCP levels based on the use of a competitive
radioimmunoassay with a DCP polyclonal antibody
[22]. Subsequently, a monoclonal antibody enzyme
immunoassay (EIA) was developed to quantify plasma
DCP levels. Several studies reported that DCP levels
were elevated in patients with HCC with the use of this
monoclonal antibody EIA at a cutoff value of 0.1 absorb-
ance units (AU)/ml [23]. Currently, EIA (Eitest PIVKA-
II; Eisai, Tokyo, Japan) and electrochemiluminescence
(Picolumi PIVKA-II, Eisai) kits with greater sensitivity have
been developed for clinical screening of patients with small
HCCs [24,25]. Mita and colleagues showed that determin-
ation of DCP levels using the more sensitive EIA method at
a cutoff value of 40 mAU/ml had a moderate sensitivity
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in high-risk populations [26]. Because elevated DCP levels
may not be associated with increased AFP or AFP-L3/AFP
levels in HCC patients, many studies have demonstrated
that a combination of these markers has a greater sensitivity
in diagnosing HCC [27-29]. The Japanese Evidence-based
Clinical Practice Guidelines and Consensus-based Clinical
Practice Manual recommended simultaneous measurement
of DCP and AFP (or AFP-L3/AFP) for screening HCC in
high-risk populations and detecting single small HCCs with
high sensitivity and specificity [30].
Glypican-3
Glypican-3 (GPC-3) is a heparin sulfate proteoglycan
that interacts with several growth factors by binding to
the cell membrane via glycosylphosphatidylinositol
anchors [31,32]. Because GPC-3 has only been detected
in HCC cells and not in benign liver tissues, it has been
investigated as a potential biomarker for the diagnosis of
early-stage HCC [33,34]. Recent studies demonstrated
that serum GPC-3 levels were higher than 300 ng/L in
50% of early-stage HCC patients with serum AFP levels
of <100 μg/L [35]. Serum GPC-3 levels at a cutoff value of
300 ng/L had a sensitivity and specificity for HCC diagnosis
of 47.0% and 93.5%, respectively [35]. Additionally, the
diagnostic performance of GPC-3 was increased when
tested in conjunction with human cervical cancer oncogene
and AFP [36]. Therefore, GPC-3 may have potential as a
biomarker for diagnosing early HCC and HCC screening in
high-risk populations.
Multiple index tests
All serological biomarkers described above are involved in
different pathways in hepatocarcinogenesis. In addition, it is
expected that a single biomarker would not have adequate
diagnostic accuracy to identify patients with early-stage
HCC. Therefore, it is reasonable that a combination of
these biomarkers would improve the diagnostic perform-
ance for early-stage HCC compared to single use. If avail-
able, we will investigate the diagnostic performance of these
biomarkers when used singly or in combination.
Alternative tests
Currently, serological tests and imaging can be used for
HCC surveillance; however, the use of serological tests has
not been recommended for routine screening of HCC in
Western practice guidelines [37,38]. The most widely used
imaging examination for HCC surveillance is ultrasonog-
raphy (US). A recent meta-analysis showed that US surveil-
lance in cirrhotic patients detected most HCC cases before
clinical presentation with a pooled sensitivity of 94% [39].
However, US was less sensitive for detecting early-stage
HCC with a pooled sensitivity of 63% [39]. There is little
evidence to indicate the use of other imaging techniquesincluding multi-detector computed tomography (CT) or
dynamic contrast-enhanced magnetic resonance imaging
(MRI) for HCC surveillance. Although novel genetic
markers are continuously discovered and reported, they are
not available for routine use in clinical practice.
Rationale
The efficacy of surveillance methods for HCC in high-risk
populations was evaluated in a randomized controlled trial
of 18,816 HBV-infected patients in China. This study
demonstrated that measurement of serum AFP levels and
US every 6 months was associated with a 37% reduction
in HCC-related mortality [40]. Current practice guidelines
from the American Association for the Study of Liver
Diseases (AASLD), the European Association for the
Study of the Liver (EASL), and the European Organization
for Research and Treatment of Cancer (EORTC) recom-
mend the surveillance of at-risk individuals with US every
6 months [37,38]. The combination of US with AFP is not
recommended for HCC surveillance because the small 6%
to 8% gain in the detection rate does not balance the
increase in false positive results and the cost of early-stage
HCC diagnosis in Western countries [38]. Furthermore,
US has suboptimal sensitivity for detecting early-stage
HCC. Thus, it is warranted for serological tests to help
identify patients with early-stage HCC that will have better
survival following curative treatment (resection, liver
transplantation, or ablation). Recently, several serological
tests including AFP-L3/AFP, DCP, and GPC-3 have been
widely investigated as diagnostic markers for early-stage
HCC in at-risk populations. In this systematic review, we
aim to determine the diagnostic performance of AFP,
AFP-L3/AFP, DCP, and GPC-3 for HCC detection,
particularly early-stage tumors meeting the Milan criteria
(single nodule <5 cm or three nodules each <3 cm in
diameter). Identifying the potential role of these new diag-
nostic biomarkers in the existing diagnostic pathways will
be useful in designing future studies to evaluate the accur-
acy of diagnostic tests and to understand study results.
Objectives
Our primary objective is to determine and compare the
diagnostic performance of AFP, AFP-L3/AFP, DCP, and
GPC-3, either singly or in combination, for early-stage HCC
diagnosis. Our secondary objective is to evaluate the poten-
tial role of these new diagnostic biomarkers, either singly or
in combination, in the existing diagnostic pathways [41].
Methods/design
Criteria for considering studies for this review
Types of studies
We will include cross-sectional studies that consecutively
or randomly recruit target populations. The index tests
and reference standards should ideally be performed on
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studies because such studies are likely to overestimate
diagnostic performance [42]. In addition, the measures
of accuracy may vary with the prevalence and stage-
distribution of the target condition [43].
Participants
High-risk populations are defined as adult patients in
whom HCC surveillance is recommended by the clinical
practice guidelines of AASLD, EASL, and EORTC.
According to AASLD guidelines, populations at high risk
of HCC include Asian male HBV carriers over age 40
years; Asian female HBV carriers over age 50 years; HBV
carriers with a family history of HCC; African/North
American Blacks with hepatitis B; cirrhotic HBV carriers;
patients with hepatitis C cirrhosis; patients with stage 4
primary biliary cirrhosis; and patients with cirrhosis due to
genetic hemochromatosis, alpha 1-antitrypsin deficiency, or
other etiologies. According to EASL guidelines, high-risk
populations are cirrhotic patients, non-cirrhotic HBV
carriers with active hepatitis or family history of HCC,
and non-cirrhotic patients with chronic hepatitis C
and advanced liver fibrosis F3. The diagnosis of liver
cirrhosis and chronic viral hepatitis in primary studies
will be assessed. Exclusion criteria are defined as pri-
mary studies that mainly recruit low-risk populations
(healthy populations or participants without any pre-
disposing factors for developing HCC).
Index tests
The index tests include AFP, AFP-L3/AFP, DCP, and GPC-3




The target condition will be proven HCC.
Reference standards
Studies will be eligible for this review if clinical diagnostic
criteria recommended by the AASLD or EASL-EORTC
were used as the primary reference standards. The
pathological diagnosis of HCC is recommended for all
nodules occurring in non-cirrhotic livers and for those
cases with inconclusive non-invasive diagnosis of HCC
in cirrhotic livers. In cirrhotic patients, non-invasive
diagnosis of HCC is established when one imaging
technique for nodules >2 cm and two imaging techniques
(multi-detector CT and dynamic contrast-enhanced MRI)
for nodules 1 cm to 2 cm in diameter reveal HCC
radiological hallmarks (arterial hypervascularity and
venous/late phase washout). Because clinical practiceguidelines are routinely updated, we will use the criteria of
reference standards that the primary studies adopted.
Search methods for identification of studies
Electronic searches
We will search the following databases: CENTRAL
(the Cochrane Library, latest issue February 2013),
Medline (January 1950 to February 2013), Embase
(January 1980 to February 2013), Science Citation Index
(January 1981 to February 2013), and the Chinese National
Knowledge Infrastructure (January 1997 to February 2013).
We will also search the Meta-analyses van Diagnostisch
Onderzoek (MEDION) and Aggressive Research Intelligence
Facility (ARIF) databases to identify diagnostic systematic
reviews that include primary studies. Language restrictions
will not be applied. The searches will be refined using the
Boolean term “AND” between the topics of HCC and index
tests (AFP, AFP-L3/AFP, DCP, and GPC-3). The details of
the Medline database search are provided below.
Searching strategies of the Medline database
1. Carcinoma, Hepatocellular
2. hepatocellular Carcinoma.mp.







10. cancer of liver.mp.
11. hepatic tumor.mp.
12. hepatic tumour.mp.








20. alpha 1 fetoprotein.mp.
21. alpha-fetoglobulin.mp.
22. alpha fetoglobulin.mp.
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39. Protein induced by vitamin K absence*.mp.








48. 41 or 42 or 43 or 44 or 45 or 46 or 47
49. 23 or 33 or 40 or 48
50. 13 and 49
Searching other resources
Reference lists of relevant reviews will be searched for
additional trials.
Data collection and analysis
Selection of studies
Two authors (TSH, YCS) will independently screen titles
and abstracts to identify potentially relevant studies. After
the screening, we will retrieve full texts of potentially
eligible studies to assess whether the individual studies
fulfill the inclusion criteria. Disagreements will be resolved
by the third author (HYC).
Data extraction and management
We will extract the following information into the
prespecified data extraction form:
1. Study characteristics (authors, year of publication,
study designs, settings, locations, and patient
enrollment strategies)
2. Test characteristics (test types, test conditions,
prespecified defined cutoff values, sampling
protocol, and criteria for test positivity)
3. Reference standards (histopathological diagnosis or
non-invasive criteria and versions of the guideline used)
4. Participant characteristics (age, gender, ethnicity,
disease types, tumor sizes, and tumor stages)
5. Statistics for meta-analysis (true positives (TP), false
positives (FP), true negatives (TN), and false
negatives (FN))
For test statistics, we will construct 2 × 2 tables to
facilitate meta-analysis of the summary estimates of
sensitivity and specificity. If these direct data are lackingin the articles, we will try to reconstruct the 2 × 2 table
using the aforementioned publication information.
Assessment of methodological quality
Methodological quality will be assessed according to the
revised tool for QUADAS-2 [44]. The full QUADAS-2
tool consists of four domains: patient selection, index
test, reference standard, and flow and timing. Each domain
will be assessed in terms of risk of bias according to the
signaling questions, and the first three domains will also be
adjudicated in terms of concerns regarding applicability.
The details are as follows:
1. Patient selection
Risk of bias: Could the selection of patients have
introduced bias?
Signaling question 1: Was a consecutive or
random sample of patients enrolled?
Signaling question 2: Did the study avoid
inappropriate exclusion?
Signaling question 3: Did the study include patients
with previous imaging studies or biomarker testing?
Applicability: Were there concerns that the
included patients and setting did not match the
review question? If the primary studies primarily
included patients with a low risk of developing
HCC, it would be of high concern regarding
applicability. If the primary studies included
patients who fulfilled the screening
recommendations of the guidelines, it would be of
low concern regarding applicability.
2. Index test
Risk of bias: Could the conduct or interpretation
of the index test have introduced bias?
Signaling question 1: If a threshold was used, was
it prespecified?
Signaling question 2: Were the index test results
interpreted without knowledge of the results of
the reference standard?
Applicability: Were there concerns that the index
test, its conduct, or its interpretation differed from
the review question?
3. Reference standard
Risk of bias: Could the reference standard, its
conduct, or its interpretations have introduced bias?
Signaling question 1: Was the reference standard
likely to correctly classify the target condition?
Signaling question 2: Were the reference standard
results interpreted without knowledge of the
results of the index test?
Signaling question 3: Was AFP incorporated into
the non-invasive criteria? (This question will be
used for evaluation of the diagnostic performance
of AFP and AFP-L3/AFP.)
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condition as defined by the reference standards
did not match the question?
4. Flow and timing
Risk of bias: Could the patient flow have
introduced bias?
Signaling question 1: Was there an appropriate
interval between the index test and reference
standard?
Signaling question 2: Did all patients receive the
same reference standard (histopathology or
non-invasive criteria for liver cirrhosis)?
Signaling question 3: Were all patients included in
the analysis?
Signaling question 4: Were all patients adequately
followed up? At least 3 months for negative results
of reference standards would be reasonable.
The signaling questions will be answered as yes, no, or
unclear. Risk of bias and concerns regarding applicability
will be rated as low, high, or unclear. Two authors
(TSH, YCS) will initially test the pilot QUADAS-2 items
in three studies. If poor agreement is noted, we will
refine the tool content and/or coding guidelines. After
reaching good agreement, we will apply the updated
form to complete the QUADAS-2 assessment for all
included studies. Discrepancies will be resolved by the
third author (HYC).
Statistical analysis and data synthesis
Descriptive analysis: this will offer an overview of all
available studies and will be presented in two separate
tables stratified by the index tests. One table will include
study design, participants, test characteristics, and refer-
ence standards. The other table will provide details on
study quality according to the review-specific QUADAS-2
tool mentioned above. The following test characteristics
will be extracted into 2 × 2 tables for all included
studies: TP, FP, TN, and FN. Study-specific estimates
of sensitivity and specificity with 95% confidence intervals
will be displayed in forest plots using Review Manager
(Version 5.2). These graphical displays will reveal the
variations in accuracy among the studies and the different
types and brands of the index tests.
Inferential statistics: we will use the bivariate random-
effects model with or without covariates to obtain sum-
mary estimates of sensitivity and specificity in studies
where a common cutoff value was applied for the inter-
pretation of the index tests [45]. Otherwise, the Rutter
and Gatsonis hierarchical summary receiver operating
characteristic (HSROC) model will be used to investigate
heterogeneity in the summary estimates of sensitivity
and specificity at different cutoff levels of the index tests
[46]. We will test for differences among the diagnostictests by including tests used as covariates in the model. It
is expected that most studies will use only one diagnostic
test, therefore, most comparisons will be indirect. However,
we may be able to investigate within study comparisons in
studies that used more than one test. The results will also
be displayed using SROC curves. The model fitting
techniques will be performed using SAS (version 9.2)
and R (version 2.15.2) software [47].
Investigations of heterogeneity
To investigate heterogeneity, we will include study design
(prospective or retrospective and year of publication),
population characteristics (gender, ethnicity, age, disease
types, and stage distribution), test characteristics (cutoff
value, test type, and number of tests per screening round),
and versions of reference standards as our study-level
variables. We will test these study-level covariates in
the bivariate model in the common threshold or add
them to the Rutter and Gatsonis HSROC model to
evaluate heterogeneity in test threshold, diagnostic accur-
acy, and the shape of curves. The likelihood ratio test will
be used to determine the statistical significance of the
covariates included in the models.
Sensitivity analyses
A sensitivity analysis will be conducted to test the
impact of the results according to the methodological
quality items rated by the QUADAS-2 tool. The reference
standards may differ slightly among the studies because
earlier studies may include AFP in the non-invasive cri-
teria to diagnose HCC. However, AFP has been removed
from the latest versions of the guidelines. Thus, there
should be some variation if the non-invasive criteria were
used to diagnose HCC. If many studies incorporate AFP
level as one of the criteria of the reference standards, we
will try to extract the data without using the AFP criterion.
If there are few studies, we will conduct sensitivity analysis
using the AFP criterion.
Assessment of reporting and publication bias
Reporting and publication bias will not be assessed for two
reasons. First, investigation of reporting and publication
bias in diagnostic accuracy studies has been shown to be
problematic because many studies are performed without
study registration [48-50]. Therefore, assessment of
publication and reporting bias from registration is not
possible. Second, funnel plot-based approaches have
been shown to be misleading for reviews of diagnostic
test accuracy [48,49].
Discussion
Our systematic review will allow patients, clinicians, and
researchers to determine the diagnostic performance of
AFP, AFP-L3/AFP, DCP, and GPC-3 for the detection of
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roles of these new diagnostic biomarkers in the existing
diagnostic pathways. This systematic review will also
help guideline developers and policy makers to provide
recommendations for the use of these serological tests in
clinical practice.
Systematic review status
The systematic review is currently in the searching and
screening phase of study eligibility. We expect to complete
the review by October 2013.
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